TY - JOUR T1 - Estimating the impact of reopening schools on the reproduction number of SARS-CoV-2 in England, using weekly contact survey data JF - medRxiv DO - 10.1101/2021.03.06.21252964 SP - 2021.03.06.21252964 AU - James D Munday AU - Christopher I Jarvis AU - Amy Gimma AU - Kerry LM Wong AU - Kevin van Zandvoort AU - CMMID COVID-19 Working Group AU - Sebastian Funk AU - W. John Edmunds Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/08/2021.03.06.21252964.abstract N2 - Background Schools have been closed in England since the 4th of January 2021 as part of the national restrictions to curb transmission of SARS-CoV-2. The UK Government plans to reopen schools on the 8th of March. Although there is evidence of lower individual-level transmission risk amongst children compared to adults, the combined effects of this with increased contact rates in school settings are not clear.Methods We measured social contacts when schools were both open or closed, amongst other restrictions. We combined these data with estimates of the susceptibility and infectiousness of children compared with adults to estimate the impact of reopening schools on the reproduction number.Results Our results suggest that reopening all schools could increase R from an assumed baseline of 0.8 to between 1.0 and 1.5, or to between 0.9 and 1.2 reopening primary or secondary schools alone.Conclusion Our results suggest that reopening schools is likely to halt the fall in cases observed in recent months and risks returning to rising infections, but these estimates rely heavily on the current estimates or reproduction number and the current validity of the susceptibility and infectiousness profiles we use.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCoMix is funded by the EU Horizon 2020 Research and Innovations Programme - project EpiPose (Epidemic Intelligence to Minimize COVID-19's Public Health, Societal and Economical Impact, No 101003688) and by the Medical Research Council (Understanding the dynamics and drivers of the COVID-2019 epidemic using real-time outbreak analytics MC_PC 19065). The following funding sources are acknowledged as providing funding for the named authors. Elrha R2HC/UK FCDO/Wellcome Trust/This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (KvZ). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: AG, WJE). FCDO/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: KvZ). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: CIJ). NIHR (PR-OD-1017-20002: WJE). UK MRC (MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics: WJE). Wellcome Trust (210758/Z/18/Z: JDM, SFunk). Department of Health and Social Care School Infection Study (PHSEZU7510) (JDM, WJE). No funding (KW). The following funding sources are acknowledged as providing funding for the working group authors. BBSRC LIDP (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda Gates Foundation (INV-001754: MQ; INV-003174: KP, MJ, YL; INV-016832: SRP; NTD Modelling Consortium OPP1184344: CABP, GFM; OPP1139859: BJQ; OPP1183986: ESN; OPP1191821: MA). BMGF (INV-016832; OPP1157270: KA). EDCTP2 (RIA2020EF-2983-CSIGN: HPG). ERC Starting Grant (#757699: MQ). This project has received funding from the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688: KP, MJ, PK, RCB, YL). FCDO/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z: CABP). This research was partly funded by the Global Challenges Research Fund (GCRF) project 'RECAP' managed through RCUK and ESRC (ES/P010873/1: TJ). HDR UK (MR/S003975/1: RME). HPRU (This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care200908: NIB). MRC (MR/N013638/1: NRW). Nakajima Foundation (AE). NIHR (16/136/46: BJQ; 16/137/109: BJQ, FYS, MJ, YL; Health Protection Research Unit for Modelling Methodology HPRU-2012-10096: TJ; NIHR200908: AJK, RME; NIHR200929: FGS, MJ, NGD; PR-OD-1017-20002: AR). Royal Society (Dorothy Hodgkin Fellowship: RL; RP\EA\180004: PK). UK DHSC/UK Aid/NIHR (PR-OD-1017-20001: HPG). UK MRC (MC_PC_19065 - Covid 19: Understanding the dynamics and drivers of the COVID-19 epidemic using real-time outbreak analytics: NGD, RME, SC, TJ, YL; MR/P014658/1: GMK). Authors of this research receive funding from UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care (TJ). UKRI Research England (NGD). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 206471/Z/17/Z: OJB; 208812/Z/17/Z: SC, SFlasche; 210758/Z/18/Z: JH, KS, SA, SRM). No funding (AMF, AS, CJVA, DCT, JW, KEA, YWDC). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participation in this opt-in study was voluntary, and all analyses were carried out on anonymised data. The study and method of informed consent was approved by the ethics committee of the London School of Hygiene & Tropical Medicine Reference number 21795.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAlthough it is not possible to share the contact survey data used to generate the contact matrices used in this analysis. The analysis code and contact matrices used are available in an online repository here: https://github.com/jdmunday/CoMix_schools_reopening https://github.com/jdmunday/CoMix_schools_reopening CIConfidence IntervalONSOffice for National StatisticsUKUnited Kingdom ER -